OCT461201 / Oxford Cannabinoid Techno, AskAt - LARVOL DELTA

Single Ascending Oral Dose Study to Investigate the Effects of OCT461201 in Healthy Volunteers (clinicaltrials.gov) - P1 | N=32 | Completed | Sponsor: Oxford Cannabinoid Technologies Holdings PLC

New P1 trial

Final Dose Administered in Phase I Clinical Trial for Lead Drug Candidate OCT461201 (OCT Press Release) - "Oxford Cannabinoid Technologies Holdings plc...is pleased to announce that the final dose of its lead pharmaceutical drug compound, OCT461201, has been successfully administered, as part of its Phase I clinical trial, with no drug adverse effects observed. The trial is being conducted in the UK in healthy volunteers by Simbec Research Limited, part of Simbec-Orion Group Ltd, using a single ascending dose protocol. The final dose was successfully administered on Wednesday, 20 September 2023, in line with the Company's previously announced timeframe. The trial's principal objective is to demonstrate the safety and tolerability of OCT461201, whilst also providing pivotal information on its pharmacokinetic profile, to confirm its value as a potential drug. The Company expects to report results by 16 October 2023."

P1 data • Trial status • CNS Disorders • Neuralgia • Pain • Peripheral Neuropathic Pain

Oxford Cannabinoid rise continues as first clinical trial gets started (Proactiveinvestors) - "Oxford Cannabinoid Technologies Holdings PLC...shares rose again after it confirmed recruitment for a phase 1 trial of its lead pain relief would start immediately after the MHRA and Welsh agency REC 2 gave their approval. OCTP will conduct the trial in healthy volunteers, with a single ascending dose protocol to test tolerability and safety. OCT461201, the drug candidate, is a cannabinoid-based pain reliever that has been shown to help patients suffering chemotherapy-induced peripheral neuropathy as well as irritable bowel syndrome."

New P1 trial • CNS Disorders • Pain

Oxford Cannabinoid interim loss nearly doubles as research costs surge (Market Screener) - "Research costs ticked up to GBP3.1 million from GBP934,513. The company said its lead drug candidate OCT461201 accounted for GBP1.5 million of the total research costs."

Commercial • CNS Disorders • Neuralgia • Pain • Peripheral Neuropathic Pain

Oxford Cannabinoid submits trials application for agonist (Market Screener) - "Oxford Cannabinoid Technologies Holdings PLC - cannabinoid medicines-focused pharmaceutical firm - Says that on Wednesday, it submitted a combined clinical trials application to the UK Medicines & Healthcare products Regulatory Agency and the Wales Research Ethics Committee 2 for its lead programme OCT461201....It will be tested in the UK in healthy volunteers to demonstrate safety and tolerability. Phase 1 of the first-in-human clinical trial is set to start in the first quarter of 2023. The company expects the trial to complete in the second quarter of 2023."

New P1 trial • CNS Disorders • Neuralgia • Pain • Peripheral Neuropathic Pain

Oxford Cannabinoid Technologies' preclinical study of lead asset returns encouraging pre-clinical results (Proactiveinvestors) - "Oxford Cannabinoid Technologies Holdings PLC...has returned some encouraging pre-clinical results for its lead asset, OCT461201....It was shown in animal models to reduce pain associated with chemotherapy-induced peripheral neuropathy (CIPN)."

Preclinical • CNS Disorders • Neuralgia • Pain • Peripheral Neuropathic Pain